CASSAVA SCIENCES INC (SAVA) Stock News

NASDAQ:SAVA - US14817C1071 - Common Stock

2.27 USD

-0.01 (-0.44%)

Last: 9/2/2025, 8:00:02 PM

2.25 USD

-0.02 (-0.88%)

Pre-Market: 9/3/2025, 7:22:21 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SAVA Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Cassava Sciences, Inc.

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

9 days ago - By: Cassava Sciences, Inc.

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

20 days ago - By: The Motley Fool

Cassava Sciences Posts Q2 Loss on Pivot

20 days ago - By: Cassava Sciences, Inc.

Cassava Reports Q2 2025 Financials Results and Provides Business Update

20 days ago - By: Cassava Sciences, Inc.

Cassava Reports Q2 2025 Financials Results and Provides Business Update

a month ago - By: Cassava Sciences, Inc.

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

a month ago - By: Cassava Sciences, Inc.

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

a month ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

a month ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

2 months ago - By: Cassava Sciences, Inc.

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

2 months ago - By: Cassava Sciences, Inc.

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

4 months ago - By: Cassava Sciences, Inc.

Cassava Reports Q1 2025 Financials Results, Provides Business Update

4 months ago - By: Cassava Sciences, Inc.

Cassava Reports Q1 2025 Financials Results, Provides Business Update

4 months ago - By: Cassava Sciences, Inc.

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

4 months ago - By: Cassava Sciences, Inc.

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

4 months ago - By: Cassava Sciences, Inc.

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

4 months ago - By: Cassava Sciences, Inc.

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

5 months ago - By: Zacks Investment Research - Mentions: BIIB LLY

Is the Future Bleak for SAVA Stock Following Another Setback?

5 months ago - By: Benzinga - Mentions: CRMD PRPH FBRX POAI ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

5 months ago - By: Benzinga

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

5 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

5 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

6 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

6 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

6 months ago - By: Cassava Sciences, Inc.

Cassava Sciences Licenses Simufilam Method of Treatment Patent

7 months ago - By: THE ROSEN LAW FIRM, P. A.

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

7 months ago - By: The Gross Law Firm

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA